The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CNMD | -22.29% | -40.88% | -9.97% | +2,770% |
| S&P | +16.9% | +95.99% | +14.39% | +1,963% |
CONMED Corp. operates as a medical technology company, which engages in the development, manufacturing, and sale of surgical devices and related equipment. It operates through the United States, Europe, Middle East, and Africa, and Asia Pacific geographical segments. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Are these three stocks sells or belles? You be the judge!
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $343.04M | 3.7% |
| Gross Profit | $180.52M | 4.3% |
| Gross Margin | 52.62% | 0.3% |
| Market Cap | $1.61B | -24.5% |
| Market Cap / Employee | $0.41M | 0.0% |
| Employees | 3.9K | -2.5% |
| Net Income | $21.42M | -28.5% |
| EBITDA | $54.89M | 9.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $33.94M | 17.5% |
| Accounts Receivable | $234.15M | -2.1% |
| Inventory | 362.3 | 12.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $881.11M | -8.7% |
| Short Term Debt | $0.71M | -0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.78% | 0.5% |
| Return On Invested Capital | 2.17% | 1.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $23.41M | -41.1% |
| Operating Free Cash Flow | $29.13M | -32.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.05 | 16.10 | 15.83 | 14.70 | -33.32% |
| Price to Book | 2.51 | 2.27 | 1.94 | 1.65 | -34.02% |
| Price to Sales | 1.74 | 1.64 | 1.44 | 1.22 | -27.89% |
| Price to Tangible Book Value | -3.98 | -4.23 | -4.05 | -3.68 | 2.19% |
| Price to Free Cash Flow TTM | 15.81 | 16.49 | 13.45 | 13.09 | -18.36% |
| Enterprise Value to EBITDA | 60.63 | 42.55 | 112.14 | 44.92 | -27.43% |
| Free Cash Flow Yield | 6.3% | 6.1% | 7.4% | 7.6% | 22.48% |
| Return on Equity | 15.2% | 14.7% | 13.0% | 11.7% | -1.44% |
| Total Debt | $940.81M | $947.16M | $892.16M | $881.83M | -8.70% |
CNMD earnings call for the period ending September 30, 2021.
CNMD earnings call for the period ending June 30, 2021.
CNMD earnings call for the period ending March 31, 2021.
CNMD earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
